Karyopharm Therapeutics, Inc. (KPTI)
1.87
-0.09
(-4.59%)
USD |
NASDAQ |
Aug 24, 16:00
1.87
0.00 (0.00%)
After-Hours: 20:00
Karyopharm Therapeutics Enterprise Value : 235.54M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 235.54M |
| August 20, 2026 | 232.37M |
| August 19, 2026 | 236.45M |
| August 18, 2026 | 234.86M |
| August 17, 2026 | 232.14M |
| August 14, 2026 | 236.90M |
| August 13, 2026 | 236.22M |
| August 12, 2026 | 237.13M |
| August 11, 2026 | 238.72M |
| August 10, 2026 | 235.54M |
| August 07, 2026 | 239.17M |
| August 06, 2026 | 235.31M |
| August 05, 2026 | 234.41M |
| August 04, 2026 | 235.54M |
| August 03, 2026 | 235.77M |
| July 31, 2026 | 234.63M |
| July 30, 2026 | 350.08M |
| July 29, 2026 | 346.67M |
| July 28, 2026 | 351.89M |
| July 27, 2026 | 351.89M |
| July 24, 2026 | 359.15M |
| July 23, 2026 | 351.89M |
| July 22, 2026 | 353.93M |
| July 21, 2026 | 369.47M |
| July 20, 2026 | 360.51M |
| Date | Value |
|---|---|
| July 17, 2026 | 406.78M |
| July 16, 2026 | 403.83M |
| July 15, 2026 | 407.23M |
| July 14, 2026 | 418.12M |
| July 13, 2026 | 419.02M |
| July 10, 2026 | 425.60M |
| July 09, 2026 | 422.43M |
| July 08, 2026 | 433.09M |
| July 07, 2026 | 419.02M |
| July 06, 2026 | 409.27M |
| July 02, 2026 | 408.82M |
| July 01, 2026 | 407.68M |
| June 30, 2026 | 412.67M |
| June 29, 2026 | 367.38M |
| June 26, 2026 | 370.20M |
| June 25, 2026 | 353.29M |
| June 24, 2026 | 345.63M |
| June 23, 2026 | 357.57M |
| June 22, 2026 | 342.92M |
| June 18, 2026 | 343.37M |
| June 17, 2026 | 351.94M |
| June 16, 2026 | 345.17M |
| June 15, 2026 | 357.35M |
| June 12, 2026 | 354.19M |
| June 11, 2026 | 342.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals, Inc. | 11.44B |
| Relay Therapeutics, Inc. | 3.368B |
| ACADIA Pharmaceuticals, Inc. | 4.195B |
| Alnylam Pharmaceuticals, Inc. | 31.27B |
| Anika Therapeutics, Inc. | 278.32M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -67.02M |
| Revenue (Quarterly) | 33.43M |
| Total Expenses (Quarterly) | 100.46M |
| EPS Diluted (Quarterly) | -2.316 |
| Gross Profit Margin (Quarterly) | 96.75% |
| Profit Margin (Quarterly) | -200.5% |
| Earnings Yield | -699.6% |
| Normalized Earnings Yield | -569.16 |